The goal of the proposed research is to characterize novel isoenzyme-selective inhibitors of histone deacetylase 6 (HDAC6) to enable human clinical investigation. Following proteasome inhibition, perinuclear aggregates of insoluble ubiquitinated proteins (termed 'aggresomes') accumulate and are degraded by autophagy. HDAC6 is a cytosolic protein mediating interactions between ubiquitinated proteins, alphatubulin and the dynein motor complex. Genetic studies of aggresome formation have demonstrated a requirement for HDAC6 enzyme function. Recent work by the candidate has credentialed HDAC6 as a cancer target in multiple myeloma, a model system for mechanistic studies of protein catabolism. Though many HDAC inhibitors are presently being prosecuted in early phase clinical development, drugs targeting HDAC6 have not been realized. Using the HDAC6-selective tool compound, tubacin, and the proteasome inhibitor, bortezomib, the applicant devised a novel anticancer strategy targeting protein catabolism with activity in preclinical models of multiple myeloma, pancreatic and ovarian cancer. Pharmacologic liabilities limit the therapeutic development of tubacin. Recent research by the applicant has resulted in a new class of highly potent bifunctional HDAC6 inhibitors (BH6-54A and BH6-1584). This research proposal outlines a biochemical study of bivalent molecular recognition and a late-phase preclinical drug development plan: in vitro toxicology, pharmacologic studies in rodents and efficacy testing in murine models of multiple myeloma. The candidate is a physician-scientist with clinical training in medical oncology and hematology. He has completed two years of post-doctoral research in chemical biology focusing on ligand discovery, protein degradation and HDAC6. His long-term goal is to establish and direct an academic research laboratory applying novel strategies in chemical biology to clinically-relevant challenges in malignant hematology. The proposed research will be carried out under the sponsorship of two mentors: Dr. Kenneth Anderson in the Division of Hematologic Neoplasia of the Dana-Farber Cancer Institute and Dr. Stuart Schreiber in the Chemical Biology Program of the Broad Institute of Harvard and MIT. This award will support a unique training experience in translational research and chemical biology, and will establish an academic pathway for the discovery and development of experimental cancer therapeutics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Jakowlew, Sonia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Hideshima, Teru; Mazitschek, Ralph; Qi, Jun et al. (2017) HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget 8:80109-80123
Hideshima, Teru; Qi, Jun; Paranal, Ronald M et al. (2016) Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A 113:13162-13167
Stubbs, Matthew C; Kim, Wonil; Bariteau, Megan et al. (2015) Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clin Cancer Res 21:2348-58
Clausen, Dane J; Smith, William B; Haines, Brandon E et al. (2015) Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole. Bioorg Med Chem 23:5061-74
Pilon, John L; Clausen, Dane J; Hansen, Ryan J et al. (2015) Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere. Cancer Chemother Pharmacol 75:671-82
Brown, Jonathan D; Lin, Charles Y; Duan, Qiong et al. (2014) NF-?B directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell 56:219-231
D'Erasmo, Michael P; Smith, William B; Munoz, Alberto et al. (2014) 7,9-Diaryl-1,6,8-trioxaspiro[4.5]dec-3-en-2-ones: readily accessible and highly potent anticancer compounds. Bioorg Med Chem Lett 24:4035-8
Guerra-Bubb, Jennifer M; Bowers, Albert A; Smith, William B et al. (2013) Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs. Bioorg Med Chem Lett 23:6025-8
French, Christopher A (2013) The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 7:11-6
Anand, Priti; Brown, Jonathan D; Lin, Charles Y et al. (2013) BET bromodomains mediate transcriptional pause release in heart failure. Cell 154:569-82

Showing the most recent 10 out of 32 publications